Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | IP6K1 | Q92551 | 14/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.74 |
| ▸ | IP6K2 | Q9UHH9 | 12/20 | 0.68 |
| ▸ | IP6K3 | Q96PC2 | 11/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30967420 | 0.97 | IP6K1 (1.00) | ALDH1A1KDM4EMEN1KMT2APOLB | |
| SCHEMBL25353212 | 0.89 | IP6K1 (0.80) | ALDH1A1KDM4EMEN1KMT2APOLB | |
| SCHEMBL25990065 | 0.85 | ALDH1A1 (0.74) | ALDH1A1KDM4EMEN1KMT2APOLB | |
| SCHEMBL6199027 | 0.85 | KDM4E (1.00) | ALDH1A1KDM4EMEN1KMT2APOLB | |
| SCHEMBL25352733 | 0.84 | KDM4E (0.73) | ALDH1A1KDM4EMEN1KMT2APOLB | |
| SCHEMBL6012040 | 0.84 | ALDH1A1 (0.73) | ALDH1A1KDM4EMEN1KMT2APOLB | |
| SCHEMBL31265142 | 0.84 | KDM4E (0.73) | ALDH1A1KDM4EMEN1KMT2APOLB | |
| SCHEMBL25989995 | 0.81 | IP6K1 (1.00) | ALDH1A1KDM4EMEN1KMT2APOLB | |
| SCHEMBL25990902 | 0.81 | ALDH1A1 (0.67) | ALDH1A1KDM4EMEN1KMT2APOLB | |
| SCHEMBL30967410 | 0.79 | IP6K1 (1.00) | ALDH1A1KDM4EMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154115-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-05-15 | — | — | US | disclosed |
| CN-118515623-B | Substituted benzisoxazole compound and application thereof in preparation of antitumor drugs | 河北中医药大学 | 2025-04-25 | — | — | CN | disclosed |
| CN-119137106-A | Arylbenzisoxazole compounds as IP6K and IPMK inhibitors and methods of use thereof | 北卡罗来纳查佩尔山大学 | 2024-12-13 | — | — | CN | disclosed |
| EP-4472954-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | The University of North Carolina at Chapel Hill (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118515623-A | Substituted benzisoxazole compound and application thereof in preparation of antitumor drugs | 河北中医药大学 | 2024-08-20 | — | — | CN | disclosed |
| WO-2023154466-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154466-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-08-17 | — | — | WO | disclosed |
| US-9763956-B2 | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy | THE BROAD INSTITUTE, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9763956-B2 | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy | THE BROAD INSTITUTE, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9320741-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-8981083-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA FARBER CANCER INSTITUTE, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981083-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA FARBER CANCER INSTITUTE, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1831170-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065204-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | PSEN2, SLC1A2, PSEN1 | ALDH1A1 1429/4885KDM4E 2474/4885MEN1 3533/4885 |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | BRPF3, EP300, BRD3 | ALDH1A1 3670/4885KDM4E 317/4885MEN1 1913/4885 |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | MYC, MYCBP, YAP1 | ALDH1A1 963/4885KDM4E 1673/4885MEN1 606/4885 |
| US-20250154115-A1 | ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF | PFKL, IP6K2, IP6K1 | ALDH1A1 851/4885KDM4E 1223/4885MEN1 4434/4885 |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | ALDH1A1 2824/4885KDM4E 1647/4885MEN1 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.